title: von Willebrand factor inhibition improves endothelial function in patients with stable angina.
abstract: ALX-0081 is a novel nano-antibody inhibiting von Willebrand factor (vWF). We evaluated whether direct inhibition of vWF by ALX-0081 improves endothelial function. Stable patients (pts, n = 55) with single vessel disease undergoing percutaneous coronary intervention (PCI) were randomized to ALX-0081 (n = 38) or placebo (n = 17). vWF inhibition was assessed by vWF antigen level (vWF:Ag) and activity by ristocetin test (vWF:RiCo). Endothelial function was assessed before (BL), 6 h and 24 h after PCI by: (a) endothelial peripheral arterial tonometry (Endoscore); (b) endothelial microparticles (EMPs) by flow cytometry. vWF:Ag and vWF:RiCo decreased within 1 h from ALX-0081. In the placebo group, no significant Endoscore changes occurred from BL to 24 h. In ALX-0081 group, Endoscore increased from BL to 24 h (p = 0.014). A decrease in EMPs was observed after ALX-0081 (p < 0.01), while no changes occurred in placebo pts. An inhibition of vWF with ALX-0081 significantly improves peripheral endothelial function.
authors.affiliation: Cardiovascular Center Aalst OLV Clinic, Moorselbaan 164, B-9300 Aalst, Belgium.
authors.forename: Olivier
authors.initials: O
authors.lastname: Muller
authors.forename: Jozef
authors.initials: J
authors.lastname: Bartunek
authors.forename: Michalis
authors.initials: M
authors.lastname: Hamilos
authors.forename: Catalina Trana
authors.initials: CT
authors.lastname: Berza
authors.forename: Fabio
authors.initials: F
authors.lastname: Mangiacapra
authors.forename: Argyrios
authors.initials: A
authors.lastname: Ntalianis
authors.forename: Kristof
authors.initials: K
authors.lastname: Vercruysse
authors.forename: Christian
authors.initials: C
authors.lastname: Duby
authors.forename: William
authors.initials: W
authors.lastname: Wijns
authors.forename: Bernard
authors.initials: B
authors.lastname: De Bruyne
authors.forename: Guy R
authors.initials: GR
authors.lastname: Heyndrickx
authors.forename: Marc
authors.initials: M
authors.lastname: Vanderheyden
authors.forename: Josefin-Beate
authors.initials: JB
authors.lastname: Holz
authors.forename: Emanuele
authors.initials: E
authors.lastname: Barbato
mesh_terms: D000368:Aged; D060050:Angina, Stable / Q000097:blood / Q000276:immunology / Q000628:therapy*; D001530:Belgium; D015415:Biomarkers / Q000097:blood; D055252:Cell-Derived Microparticles / Q000187:drug effects / Q000378:metabolism; D003324:Coronary Artery Disease / Q000097:blood / Q000276:immunology / Q000628:therapy*; D004311:Double-Blind Method; D042783:Endothelial Cells / Q000187:drug effects / Q000378:metabolism; D004730:Endothelium, Vascular / Q000187:drug effects* / Q000378:metabolism / Q000503:physiopathology; D005260:Female; D005434:Flow Cytometry; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D008297:Male; D008365:Manometry; D008875:Middle Aged; D008969:Molecular Sequence Data; D062645:Percutaneous Coronary Intervention / Q000009:adverse effects; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D011446:Prospective Studies; D061905:Single-Domain Antibodies / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome; D014841:von Willebrand Factor / Q000037:antagonists & inhibitors* / Q000276:immunology / Q000378:metabolism
chemical_list: D015415:Biomarkers; D010975:Platelet Aggregation Inhibitors; D061905:Single-Domain Antibodies; D014841:von Willebrand Factor; C585343:caplacizumab